[ Inthera Bioscience raises $10.79M in Series A Funding ]
Inthera Bioscience has raised $10.79 million in Series A Funding.
Founded in 2013, Inthera Bioscience is a a Swiss biopharmaceutical company developing first-in-class targeted small molecule therapies for solid tumors.
The company employs a proprietary technology platform to rationally design small molecule inhibitors of intracellular protein-protein interactions (PPIs). The company’s drug discovery programs are focused on the development of novel first-in-class oral agents blocking aberrant cell signaling in solid tumors, which are currently in pre-clinical development.
|Founder / CEO||Ulrich Kessler|
|Aglaia BioMedical Ventures|
|Previous Investors||EVA Basel|